Nasal allergen challenge (NAC): Practical aspects and applications from an EU/US perspective—a Work Group Report of the AAAAI Rhinitis, Rhinosinusitis and Ocular Allergy Committee - 04/05/23
the Rhinitis, Rhinosinusitis, and Ocular Allergy Committee of the AAAAI
Abstract |
Nasal allergen challenge (NAC) is applied in a variety of settings (research centers, specialty clinics, and hospitals) as a useful diagnostic and research tool. NAC is indicated for diagnosis of seasonal and perennial allergic rhinitis, local allergic rhinitis, and occupational rhinitis; to design the composition of allergen immunotherapy in patients who are polysensitized; and to investigate the physio-pathological mechanisms of nasal diseases. NAC is currently a safe and reproducible technique, although it is time- and resource-consuming. NAC can be performed by a variety of methods, but the lack of a uniform technique for performing and recording the outcomes represents a challenge for those considering NAC as a clinical tool in the office. The availability of standardized allergens for NAC is also different in each country. The objective of this workgroup report is to review the current information about NAC, focusing on the practical aspects and application for diagnosis of difficult rhinitis phenotypes (eg, local allergic rhinitis, occupational rhinitis), taking into account the particular context of practice in the United States and the European Union.
Il testo completo di questo articolo è disponibile in PDF.Key words : Allergen, challenge, nasal, obstruction, symptoms
Abbreviations used : AIT, AR, EAACI, ENT, FDA, HC, HEP, HMW, LAR, LMW, NAC, NAR, NO, OA, OR, PNIF, RNM, sIgE, SPT, TNSS, VAS
Mappa
Disclosure of potential conflict of interest: S.H. Cho reports grant support from Sanofi/Regeneron. C. Rondon reports grant and personal fees from ALK-Abelló, and personal fees from Allergopharma, LETI Pharma, Teva Pharmaceuticals, and Novartis. J.K. Han has served on scientific advisory boards for ALK-Abelló. D.K. Ledford reports research grants from AstraZeneca and Novartis; consultant fees from BioCryst, GSK, and AstraZeneca; and speaker fees from AstraZeneca, GSK, Genentech, Teva Pharmaceuticals, Sanofi/Regeneron, and MedImmune. A.N. Pepper reports grant support from Regeneron Pharmaceuticals, Pfizer, Aimmune Therapeutics, Alladapt Immunotherapeutics, ARS Pharma, Biocryst Pharmaceuticals, GENENTECH, Inc, IgGenix, Kalvista Pharmaceuticals, Novartis, Sanofi, Stallergenes Greer, Takeda Pharmaceutical Company, Gilead, and Molekule Inc. M. Wagenmann reports grants from Takeda; grants and personal fees from ALK-Abelló, AstraZeneca, GSK, Novartis, and Sanofi Aventis; and personal fees from Allergopharma, Bencard, Genzyme, Infectopharm, LETI Pharma, med update, and Stallergenes. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 151 - N° 5
P. 1215 - Maggio 2023 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?